Real-world evidence for regulatory decision-making: updated guidance from around the world

被引:2
|
作者
Burns, Leah [1 ]
Le Roux, Nadege [2 ]
Kalesnik-Orszulak, Robert [3 ]
Christian, Jennifer [4 ]
Dudinak, Jennifer [5 ]
Rockhold, Frank [6 ]
Khozin, Sean [7 ]
O'Donnell, John [1 ]
机构
[1] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ 08540 USA
[2] Bristol Myers Squibb, Regulatory Intelligence, Boudry, Switzerland
[3] Bristol Myers Squibb, Global Regulatory Sci, Princeton, NJ USA
[4] Target RWE, Durham, NC USA
[5] Bristol Myers Squibb, Global Regulatory Sci, Summit, NJ USA
[6] Duke Clin Res Inst, Dept Biostat & Bioinformat, Durham, NC USA
[7] MIT, Cambridge, MA USA
关键词
real-world evidence; real-world data; regulatory decision-making; real-world evidence regulatory frameworks; real-world data quality methods; real-world study methods; health technology assessment; SCIENTIFIC ADVICE;
D O I
10.3389/fmed.2023.1236462
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leveraging the value of real-world evidence (RWE) to make informed regulatory decisions in the field of health care continues to gain momentum. Improving clinical evidence generation by evaluating the outcomes and patient experiences at the point-of-care would help achieve the ultimate aim of ensuring that effective and safe treatments are rapidly approved for patient use. In our previous publication, we assessed the global regulatory landscape with respect to RWE and provided a review of the regional availability of frameworks and guidance through May 2021 on the basis of 3 key regulatory elements: regulatory RWE frameworks, data quality guidance, and study methods guidance. In the current review, we have updated and elaborated upon recent developments in the regulatory RWE environment from a regional perspective under the same 3 regulatory elements stated above. In addition, we have also included a new category on procedural guidance. The review also discusses the perceived gaps and potential opportunities for future development and harmonization in this field to support framework establishment in regions without pre-existing RWE policies. Additionally, the article reviews current developments of health technology assessment (HTA) bodies pertaining to RWE and discusses the status of evidentiary alignment among regulators and HTA agencies.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
    Nemeth, Bertalan
    Kamusheva, Maria
    Mitkova, Zornitsa
    Petyko, Zsuzsanna Ida
    Zemplenyi, Antal
    Dimitrova, Maria
    Tachkov, Konstantin
    Balkanyi, Laszlo
    Czech, Marcin
    Dawoud, Dalia
    Goettsch, Wim
    Hren, Rok
    Knies, Saskia
    Lorenzovici, Laszlo
    Maravic, Zorana
    Piniazhko, Oresta
    Zerovnik, Spela
    Kalo, Zoltan
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (04)
  • [42] Real-world data curation to transform medical investigation: Technology to reimagine the economics of evidence gathering and support regulatory decision-making
    Leibtag, Aaron
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2020, 23 : 44S - 47S
  • [43] Randomized Trials vs Real-world Evidence How Can Both Inform Decision-making?
    Sheldrick, R. Christopher
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (16): : 1352 - 1353
  • [44] COMMON THREADS: REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIESAVTM RECOMMENDATIONS ON REAL-WORLD EVIDENCE (RWE) USE IN DECISION-MAKING
    Jaksa, A.
    Gatto, N.
    Case, A.
    VALUE IN HEALTH, 2020, 23 : S315 - S316
  • [45] DOES REAL-WORLD EVIDENCE PLAY A ROLE IN DECISION-MAKING BY HTA BODIES FOR MEDICAL TECHNOLOGIES?
    Hartley, L.
    Gildea, L.
    Mordin, M.
    Long, J.
    D'Souza, V
    Kinderas, M.
    Ling, C.
    Warttig, S.
    VALUE IN HEALTH, 2023, 26 (12) : S434 - S435
  • [46] Real-world lung cancer screening decision-making: Barriers and facilitators
    Lowenstein, Margaret
    Vijayaraghavan, Maya
    Burke, Nancy J.
    Karliner, Leah
    Wang, Sunny
    Peters, Melissa
    Lozano, Amy
    Kaplan, Celia P.
    LUNG CANCER, 2019, 133 : 32 - 37
  • [47] Real-world and game-based learning to enhance decision-making
    Vazquez-Calatayud, Monica
    Garcia-Garcia, Raquel
    Regaira-Martinez, Elena
    Gomez-Urquiza, Jose
    NURSE EDUCATION TODAY, 2024, 140
  • [48] To Read or Not to Read a Food Label: A Real-World Decision-Making Task
    Gardiner, Jessie
    Turcotte, Josee
    Oddson, Bruce
    CANADIAN JOURNAL OF EXPERIMENTAL PSYCHOLOGY-REVUE CANADIENNE DE PSYCHOLOGIE EXPERIMENTALE, 2012, 66 (04): : 282 - 282
  • [49] Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
    Capkun, Gorana
    Corry, Sorcha
    Dowling, Oonagh
    Kolaei, Fatemeh Asad Zadeh Vosta
    Takyar, Shweta
    Furtado, Claudia
    Jonsson, Pall
    Kleinermans, Diane
    Lambert, Laurie
    Schiel, Anja
    Facey, Karen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2022, 38 (01)
  • [50] Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project
    Franklin, Jessica M.
    Pawar, Ajinkya
    Martin, David
    Glynn, Robert J.
    Levenson, Mark
    Temple, Robert
    Schneeweiss, Sebastian
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (04) : 817 - 826